BACKGROUND: The effectiveness of current treatment recommendations for vitamin D insufficiency in children with CF is unknown. Therefore, we assessed the effectiveness of vitamin D(2) 50,000 IU once daily for 28 days for vitamin D insufficiency. METHODS: Retrospective chart review of pediatric CF patients from 2006-2008. Vitamin D(2) 50,000 IU daily for 28 days was given to patients with 25-OHD <30 ng/mL and repeat 25-OHD levels were obtained after completion of therapy. RESULTS: One hundred forty-seven levels from 97 individuals were assessed. Success of treatment was 54% (n=80/147). Seventeen of 39 patients (43%) followed for an additional 6-18 months were able to maintain levels of >or=30 ng/mL. CONCLUSIONS: Vitamin D(2) 50,000 IU daily for 28 days was effective in correcting vitamin D insufficiency in approximately 50% of subjects. However, almost half of successfully treated patients were unable to maintain normal 25-OHD levels >6 months after completion of therapy, implying that this effect is transient. Copyright (c) 2010 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.
BACKGROUND: The effectiveness of current treatment recommendations for vitamin Dinsufficiency in children with CF is unknown. Therefore, we assessed the effectiveness of vitamin D(2) 50,000 IU once daily for 28 days for vitamin Dinsufficiency. METHODS: Retrospective chart review of pediatric CFpatients from 2006-2008. Vitamin D(2) 50,000 IU daily for 28 days was given to patients with 25-OHD <30 ng/mL and repeat 25-OHD levels were obtained after completion of therapy. RESULTS: One hundred forty-seven levels from 97 individuals were assessed. Success of treatment was 54% (n=80/147). Seventeen of 39 patients (43%) followed for an additional 6-18 months were able to maintain levels of >or=30 ng/mL. CONCLUSIONS:Vitamin D(2) 50,000 IU daily for 28 days was effective in correcting vitamin Dinsufficiency in approximately 50% of subjects. However, almost half of successfully treated patients were unable to maintain normal 25-OHD levels >6 months after completion of therapy, implying that this effect is transient. Copyright (c) 2010 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.
Authors: T Pincikova; K Nilsson; I E Moen; G Fluge; A Hollsing; P K Knudsen; A Lindblad; L Mared; T Pressler; L Hjelte Journal: Diabetologia Date: 2011-09-07 Impact factor: 10.122
Authors: Chiara Bertolaso; Veronique Groleau; Joan I Schall; Asim Maqbool; Maria Mascarenhas; Norma E Latham; Kelly A Dougherty; Virginia A Stallings Journal: J Pediatr Gastroenterol Nutr Date: 2014-04 Impact factor: 2.839
Authors: Ruth E Grossmann; Susu M Zughaier; Meena Kumari; Shabnam Seydafkan; Robert H Lyles; Shuling Liu; Viranuj Sueblinvong; Michael S Schechter; Arlene A Stecenko; Thomas R Ziegler; Vin Tangpricha Journal: Dermatoendocrinol Date: 2012-04-01